Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Breast Neoplasms 1228Neoplasms 1037Carcinoma, Non-Small-Cell Lung 757Prostatic Neoplasms 695Colorectal Neoplasms 597Lung Neoplasms 578Pancreatic Neoplasms 400Leukemia, Myeloid, Acute 398Neoplasm Metastasis 391Multiple Myeloma 373Ovarian Neoplasms 372Stomach Neoplasms 319Carcinoma, Hepatocellular 302Melanoma 283Brain Neoplasms 280Recurrence 278Squamous Cell Carcinoma of Head and Neck 269Head and Neck Neoplasms 239Glioblastoma 235Endometrial Neoplasms 235Triple Negative Breast Neoplasms 229Precursor Cell Lymphoblastic Leukemia-Lymphoma 225Lymphoma 225Uterine Cervical Neoplasms 224Sarcoma 202Hematologic Neoplasms 201Urinary Bladder Neoplasms 197Esophageal Neoplasms 192Carcinoma, Renal Cell 190Lymphoma, Non-Hodgkin 177

Interventions

ravulizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Atypical Hemolytic Uremic Syndrome × 1 year × Clear all
NCT06312644 2026-04-16

Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy

Alexion Pharmaceuticals, Inc.

Recruiting
75 enrolled
Classical hematology

Hemoglobinuria, Paroxysmal, Myasthenia Gravis, Neuromyelitis Optica, Atypical Hemolytic Uremic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚔